A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12P21/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12P C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, FSTA

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	_
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
X	HART R A ET AL: "Large scale, in situ isolation of periplasmic IGF-I from E. coli" BIO/TECHNOLOGY, vol. 12, November 1994 (1994-11), pages 1113-1117, XP001153305 ISSN: 0733-222X abstract page 1116, right-hand column, lines 3-50	1-3,6,9, 16-21,23
Α	WO 01/94585 A (CHAPMAN ANDREW PAUL; KING DAVID JOHN (GB); ATHWAL DILJEET SINGH (GB);) 13 December 2001 (2001-12-13) cited in the application page 35, line 31 - page 36, line 8 page 34, line 29 - page 35, line 17 page 38, lines 4-31 page 40, lines 7-29	1
	L	

	i
	-/
Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 'T' later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
16 December 2004	10/03/2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk	Authorized officer
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	van de Kamp, M

Introduced Internal Application No PCT/EP2004/009321

		PCT/EP2004/009321			
	Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	WO 93/06217 A (GENENTECH INC) 1 April 1993 (1993-04-01) page 30, line 30 - page 31, line 15	1			
Т	ANDERSEN D C ET AL: "Production technologies for monoclonal antibodies and their fragments" CURRENT OPINION IN BIOTECHNOLOGY, vol. 15, no. 5, October 2004 (2004-10), pages 456-462, XP004588033 ISSN: 0958-1669 page 456, right-hand column, line 3 - page 457, left-hand column, line 12				
X	EP 0 177 343 A (GENENTECH INC) 9 April 1986 (1986-04-09) page 6, line 33 - page 7, line 12 page 7, line 20 - page 9, line 6 page 20, line 15 - page 22, line 4 example 8 claims 12,13,15,16	1,6, 9-12, 16-23			
X	WO 03/004599 A (PANCER ZEEV; PELEG YOAV (IL); INSIGHT STRATEGY & MARKETING L (IL)) 16 January 2003 (2003-01-16) examples 2,3	1-5,14, 15,17-23			
A	EP 0 974 654 A (MITSUI CHEMICALS INC) 26 January 2000 (2000-01-26) paragraphs '0066!, '0067! examples 1-3	1			
A	EP 0 587 427 A (MITSUI TOATSU CHEMICALS) 16 March 1994 (1994-03-16) examples 3,4	1			
A	DE OLIVEIRA J E ET AL: "High-yield purification of biosynthetic human growth hormone secreted in Escherichia coli periplasmic space" JOURNAL OF CHROMATOGRAPHY A, ELSEVIER SCIENCE, NL, vol. 852, no. 2, 13 August 1999 (1999-08-13), pages 441-450, XP004177405 ISSN: 0021-9673 paragraph 2.2	1			
Α	WO 01/57217 A (CHOI KI DOO; KWON SE CHANG (KR); BAE SUNG MIN (KR); JUNG SUNG YOUB (K) 9 August 2001 (2001-08-09) comparative example 2 examples 3,4 table I	1			

Interponal Application No PCT/EP2004/009321

		PCT7EP2004/009321
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HANNIG G ET AL: "Strategies for optimizing heterologous protein expression in Escherichia coli" TRENDS IN BIOTECHNOLOGY, vol. 16, no. 2, February 1998 (1998-02), pages 54-60, XP004107042 ISSN: 0167-7799 figure 2 page 58, left-hand column, lines 13-45	
A	MIDDELBERG A P J: "Process-scale disruption of microorganisms" BIOTECHNOLOGY ADVANCES, vol. 13, no. 3, 1995, pages 491-551, XP004045404 ISSN: 0734-9750 the whole document	
A	BANEYX F: "Recombinant protein expression in Escherichia coli" CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 5, October 1999 (1999-10), pages 411-421, XP001041299 ISSN: 0958-1669 page 418, left-hand column, lines 4-49	

Information on patent family members

International Application No PCT/EP2004/009321

-		_ _		PCT7E	P2004/009321
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0194585	0194585 A		AU	6051101 A	17-12-2001
		13-12-2001	BG	106278 A	29-12-2002
			BR	0106682 A	14-05-2002
			CA	2380298 A1	13-12-2001
			CN	1383450 T	04-12-2002
			CZ	20020837 A3	15-05-2002
			DE	10192353 TO	
			EP	1287140 A1	22-05-2003
			WO		05-03-2003
				0194585 A1	13-12-2001
			GB	2366800 A	20-03-2002
			HU	0202346 A2	28-10-2002
			JP	2003535591 T	02-12-2003
			MX	PA01013440 A	04-09-2003
			NO	20020554 A	08-04-2002
			NZ	516596 A	30-07-2004
			PL	353960 A1	15-12-2003
			SK	3152002 A3	02-07-2002
			US	2003026805 A1	06-02-2003
			US	2002151682 A1	17-10-2002
			ŽΑ	200200097 A	06-01-2003
WO 9306217	Α	01-04-1993	CA	2116774 A1	01-04-1993
			EP	0604580 A1	06-07-1994
			EΡ	0861893 A2	02-09-1998
		•	JP	6510904 T	08-12-1994
			JP	2004041240 A	12-02-2004
			WO	9306217 A1	01-04-1993
			US	5648237 A	15-07-1997
EP 0177343	Α	09-04-1986	US	4680262 A	14-07-1987
	••	03 01 2300	US	4963495 A	16-10-1990
			AT	78515 T	15-08-1992
			DE	3586386 D1	27-08-1992
			DE	3586386 T2	14-01-1993
			EP	0177343 A1	
			JP	2521413 B2	09-04-1986
			JP		07-08-1996
			JP	6296491 A	25-10-1994
				2102975 C	22-10-1996
			JP	8015440 B	21-02-1996
			JP	61092575 A	10-05-1986
			JP	2575642 B2	29-01-1997
			JP	62500554 T	05-03-1987
			KR	9402814 B1	02-04-1994
WO 03004599	Α	16-01-2003	WO	03004599 A2	16-01-2003
EP 0974654	Α	26-01-2000	AU	731758 B2	05-04-2001
			ÄÜ	3801899 A	03-02-2000
			ΕP	0974654 A2	26-01-2000
			ĴΡ	2000078989 A	21-03-2000
			KR	2000070909 A 2000011587 A	25-02-2000
			ÜS	6160089 A	12-12-2000
			US	6436674 B1	
				04300/4 BI 	20-08-2002
EP 0587427	Α	16-03-1994	DE	69318909 D1	09-07-1998
			DE	69318909 T2	24-12-1998
			EP JP	0587427 A1	16-03-1994

information on patent family members

Interceponal Application No PC1/EP2004/009321

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0587427	87427 A		JP	6269292 A	27-09-1994
			US	5496713 A	05-03-1996
WO 0157217	A	09-08-2001	KR	2001073658 A	01-08-2001
			ΑU	762053 B2	19-06-2003
			ΑU	2890901 A	14-08-2001
			BR	0107708 A	19-11-2002
			CA	2397527 A1	09-08-2001
			CN	1418251 T	14-05-2003
•			EP	1250439 A1	23-10-2002
			JP	2003521925 T	22-07-2003
			WO	0157217 A1	09-08-2001
			NZ	520076 A	25-07-2003
			RU	2230116 C2	10-06-2004
			US	2004151695 A1	05-08-2004